Under a new deal with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), Sanofi (Euronext:SAN; NASDAQ:SNY) will produce more than 100 million doses of COVID-19 vaccine Cormirnaty in Europe in 2021. Sanofi spokesperson Nicolas Kressmann said...

George Chen’s D3 Bio is prioritizing  its internal pipeline so it can be choosy about in-licensed assets. The Shanghai company unveiled a $200 million series A round on Nov. 17 that was backed...

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry....

Qiming Venture Partners chose to focus its first ex-China fund on healthcare because the firm sees more interest in cross-border collaborations in life sciences than some of the other industries it invests in. Qiming unveiled...

Qiming Venture Partners closed two U.S. dollar funds and one renminbi fund totaling nearly $1.4 billion on April 16. Qiming Venture USD Fund VI closed with $935 million and Qiming Venture RMB Fund V raised...

Qiming Venture Partners closed two U.S. dollar funds and one renminbi fund totaling nearly $1.4 billion. Qiming Venture USD Fund VI closed with $935 million and Qiming Venture RMB Fund V raised RMB2.1 billion ($334.3...

Frontline Bioventures closed its second renminbi fund and third overall, bringing the firm's total under management to more than RMB3 billion ($435 million). Founder and Managing Partner Leon Chen declined to disclose the new fund's...